[ad_1]
Novo Nordisk’s weight loss drugs Ozempic and Wigoby are popular and powerful. Like, it’s really popular. Because it is very popular, Increase the GDP of the company’s home country Denmark. Because it is very popular, Food company executives are making nervous phone calls. When the patient does not want to eat, he seeks advice from Lars Fluergaard Jorgensen, CEO of Novo Nordisk. And now the company is teasing a pill that could be twice as effective.
Novo Nordisk told investors that an early-stage trial found that the oral version of amicletin led to a 13% weight loss after 12 weeks of treatment. Novo Nordisk shares rose more than 8% in Monday morning trading to a record high of about $135 per share.
read more: Three food and beverage chains plan to benefit from the rise of Ozempic
Research involved Administer tablets codenamed NNC0487-0111 A study of obese Japanese men is still ongoing at a clinic in Fukaoka, Japan. Phase 1 trials like the one that produced the results that Nordisk boasts are at the very early stages of a process that can take several years and are much smaller than Phase II, III, and IV trials. . Phase 1 trials are much larger and may lead to different results. The results take into account a variety of factors.
But if things go well, the new drug will cause weight loss twice as fast as Wigoby, which causes patients to lose 6% of their body weight over 12 weeks. Being a pill may make it easier to take than Ozempic or Wigoby, both of which require injections.
Wednesday’s share price move was enough to boost Novo Nordisk’s share price, which has already risen 33% this year, Reuters reported. More valuable than Tesla or the 12th most valuable company In the world.
[ad_2]
Source link
